Every 10-Q that Cardlytics (CDLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDLX filings page.
Cardlytics, Inc. reported Q2 2026 revenue of $36.9 million, down from $58.0 million a year earlier, as a U.S. financial-institution partner exited its platform and Monthly Qualified Users decreased. Continuing-operations net loss was $8.7 million and total net loss was $14.9 million.
The company completed the Bridg business sale, recording a $13.9 million gain in discontinued operations and later selling the 1.81 million PAR shares for $23.0 million, incurring a $2.4 million loss on investments. Cash and cash equivalents declined to $28.0 million, with $15.0 million drawn on a revolving credit facility and $172.5 million of 4.25% Convertible Senior Notes outstanding. Adjusted EBITDA was positive at $1.7 million in Q2, while stockholders’ equity stood at a $16.0 million deficit after a 1‑for‑10 reverse stock split reduced common shares outstanding to about 5.9 million.
Cardlytics, Inc. reported a narrower net loss of $4.5M for the quarter ended March 31, 2026, compared with $13.3M a year earlier, helped by income from discontinued operations. Revenue from continuing operations fell to $34.3M from $56.4M as Billings declined and Cardlytics Monthly Qualified Users dropped by 17.9 million, or 8%, following the exit of a major U.S. financial institution partner. Adjusted Contribution decreased to $19.7M, and Adjusted EBITDA was modestly positive at $0.2M. The company completed the divestiture of its Bridg business to PAR Technology, recording a $14.5M gain reported in discontinued operations. Cardlytics ended the quarter with $35.7M in cash and equivalents, $24.1M in marketable securities, and total debt of $204.2M, including $169.1M of 2024 Convertible Senior Notes and $35.1M outstanding under its revolving line of credit.
Cardlytics (CDLX) reported Q3 2025 results showing lower revenue and a large non-cash impairment. Revenue was $52.0 million versus $67.1 million a year ago, reflecting weaker served-based activity while engagement-based revenue grew.
The company recorded $58.8 million of impairment on goodwill and intangible assets, driving an operating loss of $68.9 million and a net loss of $72.7 million for the quarter. Cash and cash equivalents were $43.9 million as of September 30, 2025, with net cash used in operating activities of $3.7 million year-to-date.
On capital structure, Cardlytics fully repaid the remaining $46.1 million of its 2020 convertible notes and had $168.6 million net carrying amount of 4.25% convertible notes due 2029. It also had $46.1 million outstanding on its revolving line of credit. Stockholders’ equity moved to a deficit of $4.7 million, largely due to the impairment. The company recognized a $2.8 million employee retention credit benefit in operating expenses and implemented cost-saving measures, with additional one-time charges expected after quarter-end.